Last updated: February 19, 2026
This report analyzes Brazilian patent application BR112012000204, focusing on its granted claims, the technological scope it covers, and its position within the broader patent landscape. The patent, filed by Bayer Intellectual Property GmbH, relates to a novel crystalline form of rivaroxaban (Xarelto®). This crystalline form, designated as Form I, aims to improve the physicochemical properties of the active pharmaceutical ingredient (API), potentially impacting formulation stability, bioavailability, and manufacturing processes.
What is the Granted Claimed Subject Matter?
The granted claims for BR112012000204 define a specific crystalline form of rivaroxaban and its uses. The core of the patent lies in the characterization and assertion of a particular polymorphic state of the drug substance.
Claim 1 of the patent, which is the independent claim, defines:
A crystalline form of 3- [4-(5-chloropyridin-2-yl)phenyl]-N-{[4-(morpholin-4-yl)phenyl]methyl}-2-oxazolidinone, characterized by having an X-ray powder diffraction diagram comprising at least the following diffraction peaks: 2θ (±0.2°) at approximately 6.3°, 12.7°, 19.1°, 20.7°, 22.4°, 24.7°, 25.5°, and 27.2°. [1]
This claim is highly specific, focusing on the unique diffraction pattern that identifies the claimed crystalline form. This pattern is a fingerprint for the solid-state structure of the compound.
Subsequent dependent claims further elaborate on this crystalline form by adding additional characterization data:
- Claim 2: Claims the crystalline form according to claim 1, wherein the X-ray powder diffraction diagram comprises at least the following diffraction peaks: 2θ (±0.2°) at approximately 6.3°, 10.0°, 12.7°, 14.6°, 17.0°, 19.1°, 20.7°, 21.2°, 22.4°, 24.7°, 25.5°, 27.2°, and 30.9°. [1]
- Claim 3: Claims the crystalline form according to claim 1 or 2, wherein the X-ray powder diffraction diagram comprises at least the following diffraction peaks: 2θ (±0.2°) at approximately 6.3°, 10.0°, 12.7°, 14.6°, 17.0°, 17.6°, 19.1°, 20.7°, 21.2°, 22.4°, 24.7°, 25.5°, 27.2°, 27.9°, 30.9°, and 32.5°. [1]
These claims progressively narrow the scope by including more diffraction peaks, thereby providing a more detailed and robust characterization of the specific polymorph.
Beyond the crystalline form itself, the patent also claims its applications:
- Claim 4: Claims a process for the preparation of the crystalline form according to any of claims 1 to 3. [1] This claim covers methods of manufacturing the specific polymorph.
- Claim 5: Claims a pharmaceutical composition comprising the crystalline form according to any of claims 1 to 3 and at least one pharmaceutically acceptable carrier. [1] This claim covers the formulation of the drug product using the patented crystalline form.
- Claim 6: Claims the crystalline form according to any of claims 1 to 3 for use in the treatment or prevention of a thrombotic disorder. [1] This claim directly links the patented crystalline form to its therapeutic use, a common practice for drug patents.
What is the Technological Scope of the Patent?
The technological scope of BR112012000204 is centered on solid-state chemistry and pharmaceutical formulation, specifically pertaining to rivaroxaban. It addresses the challenge of controlling the polymorphic form of an active pharmaceutical ingredient, which is critical for drug performance and manufacturability.
The patent’s scope can be understood through several key aspects:
-
Polymorphism Control: The primary technological contribution is the identification and characterization of a specific crystalline form (Form I) of rivaroxaban. Polymorphism refers to the ability of a solid material to exist in more than one crystalline form. Different polymorphs can exhibit varying physical properties such as solubility, dissolution rate, stability, hygroscopicity, and mechanical properties (e.g., compressibility). By claiming Form I, the patent aims to protect a form that likely offers advantages over other existing or potential polymorphs.
-
Analytical Characterization: The patent relies heavily on X-ray powder diffraction (XRPD) as the key analytical technique to define and distinguish Form I. The specific 2θ angles listed in the claims represent the unique crystallographic structure of this form. Other analytical techniques, often used in conjunction with XRPD, such as differential scanning calorimetry (DSC) and infrared spectroscopy (IR), would likely be employed to further confirm the identity and purity of Form I, although XRPD is the defining characteristic in the claims.
-
Manufacturing Processes: Claim 4 indicates that the patent also covers specific methods for producing this particular crystalline form. This could involve particular crystallization conditions, solvent systems, temperature profiles, or seeding techniques designed to reliably yield Form I and exclude other polymorphs. Controlling the manufacturing process is essential to ensure that only the patented form is produced, thereby preventing circumvention.
-
Pharmaceutical Formulations: Claim 5 extends the patent protection to any pharmaceutical composition containing Form I. This means any drug product (e.g., tablets, capsules) formulated using this specific crystalline form falls under the patent's purview. This scope is broad, covering the final dosage form, irrespective of other excipients or manufacturing methods used to create the formulation, as long as Form I is present.
-
Therapeutic Applications: Claim 6 asserts the use of Form I in treating or preventing thrombotic disorders. Rivaroxaban is a direct oral anticoagulant (DOAC) and is widely prescribed for conditions such as deep vein thrombosis (DVT), pulmonary embolism (PE), and stroke prevention in patients with atrial fibrillation. This claim links the specific crystalline form to the established therapeutic indications of rivaroxaban, reinforcing its commercial value.
The overall technological scope is therefore focused on creating and utilizing a well-defined, potentially superior solid-state form of rivaroxaban for therapeutic purposes. This strategy is common in the pharmaceutical industry to extend patent protection beyond the initial composition of matter patent, by protecting improvements in the drug substance's physical characteristics or manufacturing processes.
What is the Patent Landscape for Rivaroxaban Crystalline Forms?
The patent landscape for rivaroxaban, particularly concerning its crystalline forms, is robust and has been actively developed to protect the drug substance and its various manifestations. Bayer Intellectual Property GmbH, the assignee of BR112012000204, has a significant portfolio of patents covering rivaroxaban.
Key aspects of the rivaroxaban patent landscape include:
-
Original Composition of Matter Patents: The initial patents would have covered the rivaroxaban molecule itself. These are typically the broadest and most foundational patents for a new drug.
-
Polymorph Patents: As seen with BR112012000204, companies frequently file patents on specific crystalline forms (polymorphs) of the active pharmaceutical ingredient. Rivaroxaban has multiple known crystalline forms, and each can be patented if it exhibits novel and inventive properties, such as improved stability, dissolution profiles, or manufacturability. Patents for different polymorphs can create a layered defense, blocking generic competitors from using advantageous solid forms even after the original composition patent expires.
- Rivaroxaban Polymorphs: Bayer has patents covering various forms, often designated by Roman numerals or other identifiers (e.g., Form I, Form II, Form X, Form V). BR112012000204 specifically targets Form I. Other forms might have different XRPD patterns, thermal properties, and stability characteristics.
- Examples of Polymorph Claims: While not specifically analyzed here, patents related to rivaroxaban often claim specific XRPD peaks, DSC thermograms, or IR spectral data to define novel polymorphs. The claims in BR112012000204 are representative of this approach.
-
Salt and Solvate Patents: Beyond crystalline forms, patents may also cover specific salt forms or solvates of rivaroxaban. Salts can alter solubility and bioavailability, while solvates involve the incorporation of solvent molecules into the crystal lattice, which can affect stability and other properties.
-
Process Patents: Patents for improved manufacturing processes are also common. These can cover novel synthesis routes, purification methods, or specific crystallization techniques that lead to higher yields, purity, or desired polymorphic forms. Claim 4 in BR112012000204 falls into this category.
-
Formulation Patents: Patents on specific pharmaceutical compositions or dosage forms containing rivaroxaban can provide further protection. These might claim specific excipient combinations, drug delivery systems, or tablet formulations that enhance efficacy, patient compliance, or stability. Claim 5 in BR112012000204 covers this aspect.
-
Method of Treatment Patents: Patents for new therapeutic uses or improved methods of treatment using rivaroxaban can also be filed. This is less common for well-established drugs but can occur if new indications are discovered or novel treatment regimens are developed. Claim 6 in BR112012000204 relates to this.
Competitive Landscape:
The primary competitors in the rivaroxaban market are generic manufacturers seeking to enter the market once the key patents expire. The strength and breadth of Bayer's patent portfolio, including patents like BR112012000204, are designed to prevent or delay generic competition.
- Generic Entry Strategies: Generic companies typically aim to develop non-infringing processes and formulations. This often involves identifying and using alternative crystalline forms of the API that are not covered by existing polymorph patents or developing different manufacturing processes that avoid patented steps.
- Patent Challenges: Generic companies may also challenge the validity of existing patents through litigation or administrative proceedings, arguing that the claimed inventions are not novel, obvious, or lack sufficient inventive step.
- Evergreening: The strategy of filing multiple patents for different aspects of a drug (e.g., new polymorphs, formulations, delivery systems) is often referred to as "evergreening." This approach aims to extend market exclusivity beyond the expiration of the original patent. BR112012000204 is an example of such a strategy.
Brazil-Specific Considerations:
Brazil's patent law, governed by the National Institute of Industrial Property (INPI), follows international patentability standards. However, local patent prosecution can involve specific examination practices and timelines. For pharmaceutical patents, issues like patent linkage with regulatory approval (ANVISA) and compulsory licensing provisions are relevant considerations in the Brazilian market. The patentability of polymorphs hinges on demonstrating novelty and inventive step.
In summary, BR112012000204 is part of a comprehensive strategy by Bayer to protect its intellectual property surrounding rivaroxaban by securing patent claims on a specific, analytically defined crystalline form. The patent landscape is characterized by multiple layers of protection, including composition of matter, polymorphs, processes, and formulations, all designed to maintain market exclusivity for the drug.
What are the Potential Implications for Generic Manufacturers?
The existence and scope of patent BR112012000204 have significant implications for generic manufacturers seeking to produce and market rivaroxaban in Brazil. The granted claims, particularly those defining the specific crystalline form, present direct barriers to market entry.
Key implications include:
-
Direct Infringement Risk: Generic manufacturers aiming to use rivaroxaban crystalline Form I, as defined by the XRPD peaks in Claim 1 and its dependent claims, risk direct patent infringement. This is the most immediate and significant implication. Any product or process that utilizes this specific crystalline form without a license would be in violation of the patent.
-
Need for Alternative Polymorphs: To circumvent BR112012000204, generic companies must develop rivaroxaban formulations using a crystalline form that is not claimed by Bayer. This requires extensive solid-state research and development to identify and characterize novel polymorphs or to use polymorphs that are already in the public domain or covered by expired patents.
- Novel Polymorph Discovery: Identifying a new, patentable polymorph of rivaroxaban that also exhibits favorable properties for formulation and bioavailability is a technically challenging and time-consuming process.
- Public Domain Polymorphs: If other rivaroxaban polymorphs exist and their patent protection has expired or they were never patented, these could be viable alternatives. However, these alternatives must demonstrate comparable or acceptable performance characteristics.
-
Process Infringement Considerations: Claim 4, which covers the process for preparing the crystalline form, adds another layer of complexity. Generic manufacturers must ensure that their manufacturing processes for the chosen crystalline form do not infringe on any patented methods described or claimed within the patent. This may necessitate the development of entirely new synthetic or crystallization routes.
-
Formulation Challenges: Even if a generic manufacturer successfully develops a non-infringing crystalline form, they must still develop a stable and bioavailable pharmaceutical composition. Claim 5 protects any pharmaceutical composition containing Form I. Therefore, if Form I is used, the formulation itself is protected. This reinforces the need to use a different polymorph. Even with a different polymorph, formulation development must be robust to meet regulatory standards.
-
Patent Validity Challenges: Generic companies may consider challenging the validity of BR112012000204. This could involve arguing that Form I is not novel, is obvious in light of prior art, or that the patent lacks sufficient description or enablement. Such challenges are costly and uncertain.
-
Licensing Negotiations: If developing an alternative form proves too difficult or uneconomical, generic manufacturers might explore licensing negotiations with Bayer. This would involve paying royalties for the right to use the patented Form I or its associated manufacturing processes. Such licenses are typically granted closer to patent expiry or under specific market conditions.
-
Timing of Market Entry: The effective patent expiry date for BR112012000204 will dictate when generic entry becomes feasible without infringement risk or prior licensing. Generic manufacturers must carefully track patent expiry dates and any extensions (e.g., due to patent term adjustments or supplementary protection certificates, though less common in Brazil for this type of patent).
-
Regulatory Hurdles: Beyond patent concerns, generic manufacturers must obtain regulatory approval from ANVISA. This requires demonstrating bioequivalence to the reference product and meeting all quality and safety standards. The choice of crystalline form can impact the bioequivalence study results.
The existence of patents like BR112012000204 is a standard part of the pharmaceutical industry’s strategy to maximize the commercial life of a successful drug. For generic manufacturers, these patents represent significant hurdles that require substantial R&D investment, legal expertise, and strategic planning to overcome.
Key Takeaways
- BR112012000204 protects a specific crystalline form of rivaroxaban (Form I), characterized by unique X-ray powder diffraction (XRPD) peaks.
- The patent's scope extends to processes for preparing this crystalline form and pharmaceutical compositions containing it.
- This patent is part of Bayer's strategy to protect its rivaroxaban franchise by layering intellectual property protection beyond the original composition of matter patent.
- Generic manufacturers face direct infringement risks if they use rivaroxaban Form I as defined by the patent's claims.
- Circumventing this patent requires identifying and utilizing alternative crystalline forms of rivaroxaban that are not covered by existing claims, or developing non-infringing manufacturing processes.
- Patent validity challenges and licensing negotiations are alternative strategies for generic entry.
Frequently Asked Questions
-
What is the primary therapeutic use of rivaroxaban?
Rivaroxaban is an anticoagulant medication used to prevent and treat blood clots, including deep vein thrombosis (DVT), pulmonary embolism (PE), and to reduce the risk of stroke in patients with non-valvular atrial fibrillation.
-
Why are different crystalline forms of a drug patented?
Different crystalline forms (polymorphs) of a drug can possess distinct physical and chemical properties such as solubility, stability, dissolution rate, and manufacturability. Patenting a specific advantageous polymorph helps extend market exclusivity by protecting these improved characteristics.
-
Can generic manufacturers use rivaroxaban if patent BR112012000204 is still in force?
Generic manufacturers can produce and market rivaroxaban if they do not infringe on the claims of BR112012000204. This typically means using a different crystalline form of rivaroxaban that is not claimed by Bayer, or using a patented manufacturing process under license.
-
What is X-ray Powder Diffraction (XRPD) and why is it important in this patent?
XRPD is an analytical technique used to identify the crystalline structure of a material. The patent uses specific XRPD peak positions (2θ values) to define and distinguish the claimed crystalline form of rivaroxaban, serving as its unique fingerprint.
-
What is the potential impact of this patent on the price of rivaroxaban in Brazil?
As long as BR112012000204 remains in force and is effectively enforced, it can limit competition from generic versions of rivaroxaban that utilize the patented crystalline form, potentially contributing to higher prices compared to a market with broader generic availability.
Cited Sources
[1] Bayer Intellectual Property GmbH. (2012). Rivaroxaban crystalline form I and process for preparation thereof (Brazilian Patent Application No. BR112012000204). National Institute of Industrial Property (INPI).
